Cancer

Mutations in CSF3R common in CNL, atypical CML

(HealthDay)—In the war against cancer, it looks like matchmaking—between genes and drugs—could be an important tool, according to new research into the genetic underpinnings of two rare forms of leukemia.

Cancer

Second-line CML drugs evoke faster, better front-line remissions

Two drugs approved for treatment of drug-resistant chronic myeloid leukemia provide patients with quicker, better responses as a first therapy than the existing front-line medication, according to two studies published online ...

Cancer

Using generic cancer drug could save many millions of dollars

With the expiration in January of the patent on Gleevec, the drug that 15 years ago changed chronic myeloid leukemia (CML) from a death sentence to a treatable illness, insurance companies and patients have the opportunity ...

Cancer

Gleevec's latest approval is for pediatric cancer

(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said ...

Cancer

Three cancer scientists awarded $500K Nmedical prize

Three scientists at universities in Pennsylvania, Illinois and Oregon whose research has helped transform cancer treatment will share one of the richest prizes in medicine and biomedical research.

Cancer

Could there be a gleevec for brain cancer?

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically ...

Medications

India's top court to deliver Novartis judgment

India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG that focuses on demands by major companies that their investments be protected, against Indian companies that say they ...

Diseases, Conditions, Syndromes

Tyrosine kinase inhibitors seem safe in CML with CKD

(HealthDay)—Tyrosine kinase inhibitors (TKIs) appear to be safe in patients with chronic-phase (CP) chronic myeloid leukemia (CML) and chronic kidney disease (CKD), according to a study published online July 28 in Cancer.

Medical research

Lean despite many calories

Metabolism experts are increasingly convinced that obesity and many of the pathogenic changes it entails, such as Metabolic Syndrome and type 2 diabetes, are a result of chronic inflammatory processes in fatty (adipose) tissue. ...

Cancer

Study of two sisters sheds light on lymphoma evolution

When a 41-year-old woman was diagnosed with chronic-phase chronic myeloid leukemia, she received a bone marrow transplant and subsequent leukocyte infusion from her sister. These treatments controlled her leukemia, but seven ...

Diabetes

New hope for a type 2 diabetes cure

The cancer treatment drug Imatinib, otherwise known as Gleevec is approved to treat various forms of cancer, mostly notably chronic myeloid leukemia (CML). However, researchers have stumbled onto another possible use for ...

Medical research

New protein linked to Alzheimer's disease

After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also ...

page 5 from 20